FDA approved FoundationOne Liquid CDx for three new companion diagnostic indications: Piqray in advanced or metastatic breast cancer; Rubraca in advanced ovarian cancer; and Alecensa in a certain type of metastatic non-small cell lung cancer.
Read More
The tissue-based comprehensive genomic profiling test is currently approved as a companion diagnostic for more than 20 targeted therapies.
Read More
The study demonstrates differential glycoproteomic profiles among covid-19-symptomatic and asymptomatic patients.
Read More
Simple blood tests to replace painful, invasive biopsies for cancer diagnosis will soon become more common after several recent FDA approvals, according to a report in USA Today.
Read More
Idylla reduced EGFR mutation testing turnaround time by more than a week versus reference methods for patients with NSCLC.
Read More